NIJMEGEN, the Netherlands – 14 October 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announces that Prof. Dr. Jan Smeitink, Chief Executive Officer at Khondrion, will participate in Mitocon’s 11th Italian Meeting on Mitochondrial diseases, taking place virtually on 15-16 October 2021.
The annual meeting organized by Mitocon, Italy’s leading mitochondrial disease patient associations, brings together physicians, researchers and patients from around the world providing a unique opportunity to discuss the latest research in mitochondrial disease and the current understanding around potential pathways towards diagnosis and treatment. Since the first event in 2011, it has helped to strengthen international partnerships and collaborations between the medical community and patients, enabling knowledge sharing and the progress of research in the fight against mitochondrial diseases.
Prof. Dr. Jan Smeitink, Chief Executive Officer of Khondrion, commented: “I am pleased to be involved in this important conference that aims to stimulate discussion and promote international exchange and collaboration amongst physicians, the scientific community and patients as part of our efforts to develop new treatment options for people with mitochondrial diseases. It is through partnership, knowledge-sharing and, most importantly, engaging with patients that we will be able to tackle these severe and debilitating diseases.”
Dr. Smeitink will take part in a flash presentation and roundtable discussion titled: “Challenges and pitfalls in clinical trials design” alongside industry colleagues on Saturday 16 October from 9:00 – 11:30am (CET).
For more information on, or to register for Mitocon’s 11th Italian Meeting on Mitochondrial Diseases visit www.mitocon.it.
– ENDS –
Prof. Dr. Jan Smeitink, CEO
Tel: +31 24 7635000
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Melissa Gardiner
Tel: +44 20 3709 5700
Khondrion is a privately held clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease. Founded by Prof. Jan Smeitink, a world-leader in mitochondrial medicine, the company is advancing its proprietary science through a wholly owned clinical and preclinical small molecule pipeline of potential medicines.
The company’s in-house discovery engine is using unique live-cell imaging technologies and cell-based disease models to build a portfolio of promising compounds. Active discovery programmes are underway developing new therapies, biomarkers, and new read-out technologies in the field of primary mitochondrial diseases.
To accelerate the discovery and development of its potential medicines for primary mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally. For more information visit www.khondrion.com
About mitochondrial disease
Mitochondrial disease occurs when mitochondria, found within all cells of the human body and responsible for producing the energy necessary for cells to function, are defective. This can result in a wide range of serious and debilitating illnesses occurring shortly after birth or later in life. Signs and symptoms of these can include cognitive problems, learning disabilities, blindness, deafness, heart failure, diabetes, fatigue, intolerance to exercise, muscle weakness and gait problems, and stunted growth. Orphan diseases of the oxidative phosphorylation system like Leigh disease, MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders including MIDD (maternally inherited diabetes and deafness), LHON (Leber’s hereditary optic neuropathy) and other respiratory chain/ oxidative phosphorylation disorders, are all examples of mitochondrial disease.